Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: The CHARISMA randomized multicenter clinical trial

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Ayez, Ninos ^a   van der Stok, Eric P ^a   de Wilt, Hans ^b   Radema, Sandra A ^b   van Hillegersberg, Richard ^c   Roumen, Rudi M ^d   Vreugdenhil, Gerard ^d   Tanis, Pieter J ^e   Punt, Cornelis J ^e   Dejong, Cornelis H ^f   Jansen, Rob L ^f   Verheul, Henk M ^g   de Jong, Koert P ^h   Hospers, Geke A ^h   Klaase, Joost M ⁱ   Legdeur, Marie Cecile ⁱ   van Meerten, Esther ^a   Eskens, Ferry A ^a   van der Meer, Nelly ^a   van der Holt, Bruno ^a   Verhoef, Cornelis ^a   Grünhagen, Dirk J ^a   more..

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MÁXIMA MEDICAL CENTER   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

Clinical risk score; Colorectal liver metastases; Neo adjuvant chemotherapy; Surgical resection

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; OXALIPLATIN; PLATINUM COMPLEX;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DRUG RESPONSE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MORBIDITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ABDOMINAL SURGERY; AGED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOADJUVANT THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RISK FACTOR; SECONDARY;

ADULT; AGED; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RISK FACTORS;

EID: 84925681839     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1199-8     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2010;14(1):56-61.
3. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer. 1969;23(1):198-202.
4. van der Pool AE, Lalmahomed ZS, de Wilt JH, Eggermont AM, Ijzermans JM, Verhoef C. Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy. J Gastrointest Surg. 2009;13(5):890-5.
5. Dols LF, Verhoef C, Eskens FA, Schouten O, Nonner J, Hop WC, et al. [Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006]. Ned Tijdschr Geneeskd. 2009;153(11):490-5.
6. Primrose JN. Surgery for colorectal liver metastases. Br J Cancer. 2010;102(9):1313-8.
7. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247(1):125-35.
8. van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN, Verhoef C. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg. 2010;97(3):383-90.
9. Petrelli NJ. Perioperative or adjuvant therapy for resectable colorectal hepatic metastases. J Clin Oncol. 2008;26(30):4862-3.
10. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-42.
11. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-9.
12. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-17.
13. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697-705.
14. Araujo R, Gonen M, Allen P, Blumgart L, Dematteo R, Fong Y, et al. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol. 2013;20(13):4312-21.
15. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007-16.
16. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208-15.
17. Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, Makuuchi M. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg. 2007;142(3):269-76. discussion 277.
18. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77(7):1254-62.
19. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309-18. discussion 318-321.
20. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189(3):291-9.
21. Nagashima I, Takada T, Matsuda K, Adachi M, Nagawa H, Muto T, et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg. 2004;11(2):79-83.
22. Konopke R, Kersting S, Distler M, Dietrich J, Gastmeier J, Heller A, et al. Prognostic factors and evaluation of a clinical score for predicting survival after resection of colorectal liver metastases. Liver Int. 2009;29(1):89-102.
23. Schindl M, Wigmore SJ, Currie EJ, Laengle F, Garden OJ. Prognostic scoring in colorectal cancer liver metastases: development and validation. Arch Surg. 2005;140(2):183-9.
24. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati P. Patterns of recurrence after resection of colorectal liver metastases: prediction by models of outcome analysis. World J Surg. 2001;25(5):638-44.
25. Ueno H, Mochizuki H, Hatsuse K, Hase K, Yamamoto T. Indicators for treatment strategies of colorectal liver metastases. Ann Surg. 2000;231(1):59-66.
26. Mala T, Bohler G, Mathisen O, Bergan A, Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World J Surg. 2002;26(11):1348-53.
27. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575-80.
28. Parks R, Gonen M, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg. 2007;204(5):753-61. discussion 761-753.
29. Jarnagin WR, D'Angelica M. Systemic therapy for patients with resectable hepatic colorectal metastases: improving patient selection. Ann Surg Oncol. 2014;21(1):11-2.
30. Ayez N, Grünhagen DJ, de Jonge J, Ijzermans J, Eggermont AM, Verhoef C. The role of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. Orlando, Fl, USA: SSO (abstr 87); 2011.
31. Rahbari NN, Reissfelder C, Schulze-Bergkamen H, Jager D, Buchler MW, Weitz J, et al. Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer. 2014;14:174.
32. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
33. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-13.
34. Adam R, Bhangui P, Poston G, Mirza D, Nuzzo G, Barroso E, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010;252(5):774-87.
35. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg. 2012;255(2):237-47.
36. Hirokawa F, Hayashi M, Miyamoto Y, Asakuma M, Shimizu T, Komeda K, et al. Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol. 2014;21(1):139-46.